PCRX

Bullish

Pacira BioSciences Q1 2026 Earnings Call Transcript

Pacira BioSciences reported strong Q1 2026 results, driven by their "5 by 30" strategy, which focuses on patients served, product, revenue, profitabil...

Benzinga 2 weeks ago 0

Bullish

[8-K] Pacira BioSciences, Inc. Reports Material Event

Pacira BioSciences (NASDAQ: PCRX) reported Q1 2026 revenue of $177.4 million, a 5% increase year-over-year, driven by strong growth in its non-opioid ...

Stock Titan 2 weeks ago 0

Neutral

Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings

Pacira BioSciences Inc. (PCRX) announced its Q4 2025 earnings, reporting a revenue of $196.9 million, exceeding estimates, while diluted EPS was $0.04...

Quiver Quantitative 2 weeks ago 0